GLP-1s Might Help Your Knees, Kidneys, and Sleep — Here's What the Evidence Shows

The List of Conditions GLP-1s May Help Keeps Growing

GLP-1 receptor agonists were originally developed for type 2 diabetes. Then they were approved for weight loss. Then cardiovascular protection. Now the research frontier is expanding in directions that would have seemed implausible five years ago: osteoarthritis, chronic kidney disease, sleep apnea, addiction, and even neurodegenerative disease. A 2026 Nature Medicine review documented this expansion, noting that new indications, including substance use disorders, metabolic liver disease, arthritis, type 1 diabetes, and inflammatory bowel disease, are all under active investigation.

Here is where the evidence stands for each — separated clearly into what is proven, what is promising, and what is still speculative.

Proven: Cardiovascular Protection

This is no longer speculative. The SELECT trial demonstrated that semaglutide reduces the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in patients with obesity and established cardiovascular disease, regardless of diabetes status. This finding changed prescribing guidelines and was a major factor in the ADA's 2026 Standards of Care revision.

Proven: Kidney Protection

The FLOW trial was stopped early for efficacy — a strong signal. Semaglutide significantly reduced kidney complications in patients with type 2 diabetes and chronic kidney disease, with improvements that were independent of weight loss. In January 2025, the FDA approved Ozempic for reducing kidney disease progression. This is now a guideline-supported indication.

Promising: Osteoarthritis and Joint Pain

A 2024 study found that patients on semaglutide experienced meaningful decreases in knee osteoarthritis pain. A separate medical claims analysis suggested that semaglutide may reduce the risk of developing knee osteoarthritis. The mechanism is debated — is it weight loss reducing mechanical stress on joints, or does GLP-1 have direct anti-inflammatory effects on joint tissue? Dedicated osteoarthritis trials are now underway, and researchers at the University of Colorado have described GLP-1s as the most scientifically credible candidate for disease modification in osteoarthritis to emerge in many years.

Promising: Sleep Apnea

Obstructive sleep apnea improves with weight loss from any cause, and GLP-1-mediated weight loss is no exception. Reduced neck circumference and decreased fat deposits around the airway contribute to measurable improvements in sleep quality and apnea severity. Multiple trials are investigating whether GLP-1s could earn a formal sleep apnea indication.

Promising: Addiction and Substance Use Disorders

As covered in our companion article on the Lancet alcohol trial, GLP-1s show signal across multiple substances. A BMJ study of 600,000+ veterans linked GLP-1 use to 14% lower risk of developing any substance use disorder. A Phase 2 Lancet trial showed semaglutide reduced alcohol consumption. 33 clinical trials are now registered. This is early but extraordinarily promising.

Early Signal: Heart Failure

GLP-1 receptor agonists are being studied for heart failure with preserved ejection fraction (HFpEF) — a condition with few effective treatments. Genetic evidence suggests GLP-1 receptor activation may reduce heart failure risk through mechanisms beyond glycemic control. Peripheral artery disease is also under active FDA-track investigation.

Early Signal: Neurodegenerative Disease

Preclinical and early clinical data suggest GLP-1 receptor agonists may have neuroprotective effects relevant to Alzheimer's disease and Parkinson's disease. The mechanism may involve reduced neuroinflammation and improved cerebral blood flow. These indications are years from any clinical application, but the biological rationale is being taken seriously by major research institutions.